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Aims. CD73 is a membrane associated 5󸀠-ectonucleotidase that has been proposed as prognostic biomarker in various solid tumors.
The aim of this study is to evaluate CD73 expression in a cohort of patients with primary bladder cancer in regard to its association
with clinicopathological features and disease course.Methods. Tissue samples from 174 patients with a primary urothelial carcinoma
were immunohistochemically assessed on a tissue microarray. Associations between CD73 expression and retrospectively obtained
clinicopathological data were evaluated by contingency analysis. Survival analysis was performed to investigate the predictive value
of CD73within the subgroup of pTa and pT1 tumors in regard to progression-free survival (PFS).Results. HighCD73 expressionwas
found in 46 (26.4%) patients and was significantly associated with lower stage, lower grade, less adjacent carcinoma in situ and with
lower Ki-67 proliferation index. High CD73 immunoreactivity in the subgroup of pTa and pT1 tumors (𝑛 = 158) was significantly
associated with longer PFS (HR: 0.228;𝑝 = 0.047) in univariable Cox regression analysis.Conclusion. HighCD73 immunoreactivity
was associated with favorable clinicopathological features. Furthermore, it predicts better outcome in the subgroup of pTa and pT1
tumors and may thus serve as additional tool for the selection of patients with favorable prognosis.
1. Introduction
Bladder cancer (BC)—the 11th most commonly diagnosed
cancer worldwide [1]—presents in up to 80% of all patients
either as a noninvasive papillary carcinoma (pTa) or as a car-
cinoma invading the submucosal connective tissue (pT1) [2,
3]. However, approximately 70% of these superficial tumors
recur and up to a quarter even progress into muscle invasive
bladder cancer (MIBC) [4]. Since close cystoscopic monitor-
ing of recurrence and progression after initial transurethral
resection of the tumor causes immense healthcare costs [5],
accurate markers are needed in addition to clinicopatho-
logical factors [6] to individualize postoperative follow-up
schedules [7–9]. Although numerous studies have evaluated
the predictive value of different biomarkers in regard to
progression of superficial bladder cancer [10–19], none of
them has an established role in daily clinical practice.
CD73 (NT5E, ecto-5󸀠-nucleotidase) is a glycosylphos-
phatidylinositol- (GPI-) anchored cell-surface enzyme that
plays a crucial role in the purinergic signalling pathway by
dephosphorylating AMP (adenosine monophosphate) into
adenosine [20, 21]. Extracellular adenosine itself is involved in
tumor immunoescape and invasion of tumor cells [22], while
nonenzymatic functions of CD73 are related to cell adhesion
and migration of tumor cells [23, 24].
CD73 expression has been investigated in many different
cancer cell lines and human tumor biopsies so far and seems
to play an important role in cancer development [20, 25, 26].
The role of CD73 in bladder BC is not well known and
controversial [27–30]. Furthermore, neither larger expression
studies of CD73 in BC biopsies nor studies investigating the
predictive ability of this marker have been published so far.
The aim of the present study is to evaluate the association
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Table 1: Patient and tumor characteristics and results of immunohistochemical analyses.
Variable Categorization 𝑛 analyzablea %
Total (𝑛 = 174)a
Clinicopathologic data
Age at diagnosis (median, range):
69.5 years (32–92)
<70 years 87 50.0
≥70 years 87 50.0
Sex Female 43 24.7
Male 131 75.3
Tumor stage (WHO 1973b)
pTa 90 51.7
pT1 68 39.1
pT2 13 7.5
pT3 2 1.1
pT4 1 0.6
Histologic grade (WHO 1973b)
G1 44 25.3
G2 87 50.0
G3 43 24.7
Histologic grade (WHO 2004c) Low grade 101 58.0
High grade 73 42.0
Adjacent carcinoma in situ No 158 90.8
Yes 16 9.2
Multiplicity Solitary 124 71.3
Multifocal 50 28.7
Growth pattern Papillary 159 91.4
Solid 15 8.6
Immunohistochemistry (IHC)
CD73
Score 0 80 46.0
Score 1+ 48 27.6
Score 2+ 46 26.4
Ki-67 labelling index ≤10% 108 62.1
>10% 66 37.9
aAll patients.
bStaging and grading according to the 1973 WHO classification system.
cStaging and grading according to the 2004 WHO classification system.
between CD73 expression and tumor progression in a large
cohort of patients with primary BC.
2. Material and Methods
Tissue microarrays (TMA) were constructed from 348
formalin-fixed, paraffin-embedded urothelial BC tissues
from 174 patients as previously described [31]. Tumor samples
were represented in duplicate tissue cores with a diameter of
1mm. The collection of the specimens was performed by the
Institute of Surgical Pathology, University Hospital, Zurich,
Switzerland, between 1990 and 2006. The tissue samples in
TMA represent a series of 174 consecutive (nonselected)
primary urothelial bladder tumors consisting of 90 pTa, 68
pT1, and 16 ≥ pT2 tumors. A board-certified pathologist
(Peter Wild) reevaluated the hematoxylin-and-eosin-stained
slides of all specimens. Tumor stage and grade were assigned
according to UICC and WHO criteria. Additionally, to
analyse the immunoreactivity of CD73 in normal urothelium,
eight slides were cut from formalin-fixed, paraffin-embedded
urothelium of the bladder neck of patients without any
history of urothelial dysplasia or BC.
Retrospective clinical follow-up data were available for all
the 174 patients (100%). The median follow-up period for the
entire cohort was 110.6 months ranging from 32.4 to 226.8
months. Unfortunately, a proper analysis of adjuvant bladder
instillation therapy (BCG or chemotherapy) could not be
performed due to missing data in about 50% of the patients.
The TMA and its clinical cohort have been previously
published [32]. Descriptive characteristics of the cohort are
depicted in Table 1. The study was approved by the Cantonal
Scientific Ethics Committee Zurich (http://www.kek.zh.ch,
approval number: StV-NR. 25/2007).
TMA was freshly cut and used on 3 𝜇m paraffin sec-
tions as described previously [33].The immunohistochemical
detection of CD73 on tissue samples was performed by
use of Anti-NT5E rabbit polyclonal antibody from Sigma
Chemical Company, Saint Louis, United States (dilution
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Figure 1: Immunohistochemical staining pattern of CD73. CD73 shows a distinct membranous immunoreactivity with pronounced intensity
in the basal layer. Representative examples of score 0 (a), 1+ (b), and 2+ (c) are depicted.
1 : 500). Clone MIB-1 (dilution 1 : 50; Dako, Glostrup, Den-
mark) was used for the detection of Ki-67. Immunohisto-
chemical studies utilised an avidin-biotin peroxidase method
with a diaminobenzidine (DAB) chromogen. After antigen
retrieval (microwave oven for 30min at 250W), immuno-
histochemistry was conducted using a NEXES autostainer
(Ventana, Tucson, AZ, USA) following the manufacturer’s
instructions.
Two experienced pathologists (Lorenz Buser and Peter
Wild) evaluated all slides. Membranous CD73 immunore-
activity in the basal layer was assessed by using a semi-
quantitative three-scale scoring system ranging from 0 to 2+
(score 0: no staining; score 1+: weak staining; score 2+: strong
staining).
In the situation of observing different staining intensities
between the duplicate tissue cores, the core with more
representative tumor tissue was chosen. If both duplicate
tissue cores with different staining intensities demonstrate a
comparable amount of representative tumor tissue, the inten-
sity of the core with more homogenous staining intensity was
selected. Immunoreactivity of CD73 was dichotomized for
analytical purposes into a CD73 low-expression group (con-
taining scores 0 and 1+) and a CD73 high-expression group
(containing score 2+). The percentage of Ki-67 positive cells
of each specimen was determined as described previously
[34]. More than 10% of positive tumor cells were defined as
a high Ki-67 labelling index [35].
Statistical analyses were performed with SPSS version 22
(IBM, Armonk, USA). 𝑝 values < 0.05 were considered as
statistically significant. The statistical associations between
clinicopathological and immunohistochemical data were
analysed by using contingency tables together with Fisher’s
exact test (2-sided) for all binary variables and the Chi-
square test (2-sided) for all other nominal variables. In the
subgroup of nonmuscle-invasive bladder cancer (NMIBC,
pTa and pT1), progression-free survival (PFS) was evaluated.
Stage-shifts (from pTa to pT1-4 or from pT1 to pT2-4) or the
detection of distantmetastasis was considered as progression.
The Kaplan-Meier method was used for plotting the PFS
curves. Significant differences between the curves were
analysed by using the two-sided log-rank test. Associations
between clinicopathological/immunohistochemical data and
PFS were evaluated by univariable and multivariable Cox
regression. All significant variables in the univariable analysis
were used in the multivariable model.
3. Results
All 174 (100%) tumor samples could be evaluated for CD73
immunoreactivity. CD73 showed a membranous immunore-
activity, which was much more pronounced in the basal
layer than in the other tumor cells. Further, a faint and
inhomogeneous cytoplasmatic staining was observed inmost
of the cases with positive membranous staining. In order
to allow a distinct evaluation, only membranous CD73
immunoreactivity in the basal layer was assessed. Figure 1
shows representative examples from our TMA for each
staining score ranging from 0 to 2+.
A strong expression of CD73 (score 2+) was found in
46 of 174 patients (26.4%), whereas in 48 patients (27.6%)
a weak immunoreactivity (score 1+) was detected. Finally,
80 patients (46%) showed no CD73 staining. The distri-
bution of the dichotomized staining intensities of CD73
and Ki-67 are shown in Table 1. Additionally, we inves-
tigated 8 samples of normal urothelium (Supplementary
Figures S1A–F in Supplementary Material available online at
http://dx.doi.org/10.1155/2015/785461) of individuals without
any history of urothelial dysplasia or carcinoma.We observed
a weak and inhomogeneous expression of CD73 in the
cytoplasm and cell membrane, which was more pronounced
in the basal layer in 4 out of 6 cases (Supplementary Figures
S1A–C, F).
Table 2 shows the associations between CD73 staining
patterns and clinicopathological parameters (stage, grade,
adjacent carcinoma in situ, multiplicity, growth pattern, and
Ki-67) of the tumors. High CD73 expression is associated
with lower stage (𝑝 = 0.006), lower grade (WHO 2004,
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Table 2: Comparison of the immunohistochemical markers with pathologic characteristics (𝑛 = 174).
Variable Categorization CD73 expression
Score 0 or 1+ Score 2+ 𝑝
Tumor stage (WHO 1973)a
pTa 57 33
0.006
pT1 57 11
pT2 12 1
pT3 2 0
pT4 0 1
Histologic grade (WHO 1973)a
G1 31 13
0.100G2 60 27
G3 37 6
Histologic grade (WHO 2004)b Low grade 67 34 0.014
High grade 61 12
Adjacent carcinoma in situb No 112 46 0.007
Yes 16 0
Multiplicityb Solitary 87 37 0.130
Multifocal 41 9
Growth patternb Papillary 115 44 0.359
Solid 13 2
Immunohistochemistry
Ki-67 labelling index ≤10% 72 36 0.008
>10% 56 10
aChi-square Pearson (2-sided); bold face representing 𝑝 values <0.05.
bFisher’s exact test (2-sided); bold face representing 𝑝 values <0.05.
𝑝 = 0.014), less adjacent carcinoma in situ (𝑝 = 0.007)
and lower Ki-67 expression (𝑝 = 0.008). Contingency
table analysis for the Ki-67 labelling index and the clinico-
pathological characteristics have been previously published
[32] and showed a significant correlation (𝑝 < 0.05)
with all clinicopathological characteristics except for tumor
multiplicity.
158 out of 174 patients (90.8%) underwent TUR for a
primary pTa or pT1 urothelial carcinoma of the bladder.
This subgroup was followed for a median of 110.7 months
(range: 32.4–245.9 months). In total, 22 patients (13.9%)
showed a stage-shift. The median time to progression was
45.2 months ranging from 10.2 to 226.7 months. Kaplan-
Meier analysis shows that patients within the subgroup of low
CD73 expression have a significantly shorter PFS compared
to the subgroup of high CD73 expression (Figure 2). The
corresponding log-rank test renders a 𝑝 value of 0.030.
Growth pattern (𝑝 < 0.001) and Ki-67 (𝑝 = 0.003) were also
significantly associated with shorter PFS (Table 3).
In univariable Cox regression (Table 4), a high expression
of CD73 reduces the rate of progression (hazard ratio, HR)
by the factor of 0.228 (95% confidence interval [CI] ranging
from 0.053 to 0.978; 𝑝 = 0.047) compared to patients with
a low expression of CD73. Of all other clinicopathologic
parameters, growth pattern (HR = 7.634 [2.717–21.740]; 𝑝 <
0.001) and Ki-67 (HR = 3.356 [1.429–7.874]; 𝑝 = 0.006) were
significantly associated with reduced PFS. We performed
multivariable Cox regression analysis for all significant pre-
dictors in univariable analysis, where CD73 did not remain
a significant predictor. Only growth pattern remained an
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Figure 2: Kaplan-Meier analysis for progression-free survival com-
paring high and low CD73 expression. The log-rank test was used
for the detection of statistical significance.
independent predictor for shorter PFS (HR = 3.891 [1.245–
12.195]; 𝑝 = 0.019).
Disease Markers 5
Table 3: Analysis of factors for tumor progression.
Variable Categorization Tumor progression (TP)
𝑛a Events 𝑝b
Pathologic data
Tumor stage (WHO 1973c) pTa 90 10 0.360
pT1 68 12
Histologic grade (WHO 1973c)
G1 44 3
0.085G2 86 12
G3 28 7
Histologic grade (WHO 2004d) Low grade 99 10 0.083
High grade 59 12
Adjacent carcinoma in situ No 146 20 0.545
Yes 12 2
Multifocality
Unifocal
tumor 115 15 0.465
Multifocal
tumor 43 7
Growth pattern Papillary 151 17 <0.0001
Solid 7 5
Immunohistochemistry
CD73 Score 0 or 1+ 114 20 0.030
Score 2+ 44 2
Ki-67 labelling index ≤10% 106 9 0.003
>10% 52 13
aOnly primary pTa and pT1 tumors are included.
bLog-rank test (2-sided); bold face representing 𝑝 values <0.05.
cStaging and grading according to the 1973 WHO classification system.
dStaging and grading according to the 2004 WHO classification system.
Table 4: Regression analysis.
Variable (categorization) Univariable analysis Multivariable analysis
HR 95% CI 𝑝 value HR 95% CI 𝑝 value
Tumor stage (pTa versus pT1) 1.481 0.635 3.454 0.363
Histologic grade (WHO 2004a) 2.070 0.894 4.808 0.090
Adjacent carcinoma in situ 1.563 0.363 6.711 0.549
Multifocality 1.401 0.565 3.472 0.467
Growth pattern (papillary versus solid) 7.634 2.717 21.740 <0.001 3.891 1.245 12.195 0.019
CD73 0.228 0.053 0.978 0.047 0.319 0.072 1.408 0.132
Ki-67 3.356 1.429 7.874 0.006 2.222 0.873 5.650 0.094
aStaging and grading according to the 2004 WHO classification system.
4. Discussion
This is the first study evaluating CD73 immunoreactivity in
a large cohort of primary urothelial bladder carcinomas. We
found that high CD73 expression is associated with lower
stage, lower grade (WHO 2004), less adjacent carcinoma in
situ and lower Ki-67 expression. In the subgroup of NMIBC
(pTa and pT1), high CD73 immunoreactivity was associated
with longer PFS in univariable Cox regression analysis but
did not remain an independent predictor of longer PFS in
multivariable Cox regression analysis.
Only a few studies have evaluated the role of CD73 in BC.
Similar findings were reported by Wilson et al. who studied
neoplastic transformed rodent bladders and detected a loss
of CD73 after cancerous transformation [29]. A study using
two human bladder cancer cell lines found a CD73 activity
in the higher grade cell line of about five times as high as
in the lower grade cell line [27]. Rockenbach et al. induced
bladder cancer in mice and detected a higher expression
of CD73 in the cancerous tissue [30]. One study evaluated
CD73 enzyme activity in 36 human bladder cancer biopsies
and 9 noncancerous bladder biopsies [28]. CD73 enzyme
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activity was comparable in BC and in normal urothelial
tissue. However, contrary to our work, no follow-up data was
reported on BC patients.
Several studies have investigated CD73 immunohis-
tochemistry in other solid tumors. Interestingly, similar
results have been reported for gynaecologic neoplasias: Oh
et al. investigated 167 epithelial ovarian carcinomas and
found associations between overexpression of CD73 and
better prognosis, lower stage, and better differentiation [36].
Another study also assigning a favorable prognosis to ele-
vated CD73 expression is the one of Supernat et al. that
analysed 136 breast cancers (stages I–III) [37].
However, other investigations of CD73 in different solid
tumors found contradictory results: CD73 has been reported
as a disadvantageous prognostic or predictive factor, namely,
in colorectal, gastric, gallbladder, prostate, and some forms of
breast cancer [38–43].
Taken together, conflicting results have been published
for the role of CD73 in solid tumors. Interestingly CD73 can
be upregulated by several different mediators and conditions
such as hypoxia [44, 45] and IFN-beta [46]. Hypoxia is
a common characteristic of advanced cancers with poor
progressionwhile an increase in IFN-beta activates immunity
against tumors [47]. Presence of hypoxia or IFN-beta in these
tumors could partially explain the discrepancies. Further-
more, it is important to note that different tissues have very
different enzymatic activity of CD73 [48]. This as well can
potentially explain differences between different cancers.
In conclusion, our results are in contrast with the current
proposed concepts from some authors, where overexpression
of CD73 is considered as a disadvantageous factor in car-
cinogenesis [20, 25, 26]. In our study strong CD73 expression
was associated with low-grade tumors, known for their good
prognosis. Similar to our work, Oh and Rackley et al. could
also detect firstly an inverse relationship between grading
and expression of CD73 in epithelial ovarian carcinomas
and prostate cancers, respectively, and secondly a direct
relationship between expression of CD73 and advantageous
prognosis [36, 49]. As in our work, strong CD73 expression
was also proposed as a potential marker of good prognosis
in breast cancer [37]. Very recently, a molecular biologic link
between BC and breast cancer has been found, where a study
identified two intrinsic, molecular subsets of high-grade
BC, which have similar characteristics of subtypes of breast
cancer [50]. The results of this work suggest that molecular
characteristics of BC reflect many aspects of breast cancer.
Since CD73 promotes the hydrolysis of AMP into adenosine
and phosphate [20, 21], the results of our study could also be
explained by the proapoptotic effect of adenosine postulated
by several articles [51–53].
In our study, high CD73 expression is associated with
lower stage and grade and therefore with low risk disease.
However, we note that low CD73 expression is also present in
a distinct amount of patients with pTa tumors (𝑛 = 57, 33%;
see Table 2). According to our results presented in Table 2,
it seems that strong expression of CD73 has good specificity
(0.85) but low sensitivity (0.63) in the prediction of low risk
(pTa) tumors.
There are limitations to our study. First, this is a retro-
spective, single-institution study. Second, information about
adjuvant instillation therapy could not be evaluated.As tumor
recurrence and progression is known to vary upon instillation
therapy, it is an important missing aspect of this study. Also,
the investigated study population has been collected over
a long time period between 1990 and 2006 where clinical
practice with respect to intravesical therapy has changed.
Thus, this may have additionally influenced our study results.
However, all patients had primary (nonrecurrent) tumors and
a long follow-up period, which makes this study population
neverthelessmeaningful to study.Third, the low rate ofMIBC
patients has to be mentioned. Hence, no conclusion can be
drawn for this group of tumors. Prospective studies with a
higher proportion of MIBC are necessary to further evaluate
the role of CD73 as a biomarker in BC. Furthermore—beside
validation studies for the function of CD73 as a biomarker
in BC—more research investigating the role of CD73 as a
possible therapeutic target is warranted.
5. Conclusion
High expression of CD73 is observed in BC patients with
favorable pathological features. In NMIBC, high CD73
expression was additionally associated with good prognosis.
Besides clinical and pathological parameters, detection of
strong CD73 expression in BC may help to stratify patients
into a low risk group. Further studies are warranted to
confirm this hypothesis.
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